NT-219
- Generic Name
- NT-219
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14BrNO5S
- CAS Number
- 1198078-60-2
- Unique Ingredient Identifier
- K1WT1A1UP5
Purple Biotech Launches Phase 2 Trial of NT219 for Drug-Resistant Head and Neck Cancer
• Purple Biotech initiates Phase 2 trial of NT219, a novel dual-pathway inhibitor, in combination with pembrolizumab or cetuximab for treating recurrent/metastatic head and neck cancer.
• The study, led by Dr. Antonio Jimeno at University of Colorado, will evaluate NT219's potential to overcome tumor resistance in a $5 billion market where current treatments show only 15-20% response rates.
• NT219's unique mechanism targeting IRS1/2 and STAT3 pathways showed promising results in preclinical studies, demonstrating ability to reverse immunotherapy resistance in tumors.
BioNTech Advances Oncology Pipeline with BNT327/PM8002 and mRNA Immunotherapies
• BioNTech is progressing BNT327/PM8002, a bispecific antibody, into global clinical trials for first-line small cell lung cancer and non-small cell lung cancer.
• The company plans to initiate additional trials combining BNT327/PM8002 with antibody-drug conjugates (ADCs) in 2025, expanding its combination strategy.
• BioNTech's mRNA cancer immunotherapy, autogene cevumeran, is being evaluated in a Phase 2 trial for muscle-invasive urothelial carcinoma in combination with nivolumab.
• Clinical data readouts are expected in 2025 and 2026 from multiple randomized trials of personalized and off-the-shelf mRNA cancer immunotherapy candidates.
Purple Biotech's CM24 Combo Shows Promise in Pancreatic Cancer
• Purple Biotech's CM24, combined with Opdivo and chemotherapy, demonstrates improved overall survival in second-line metastatic PDAC patients.
• The combination therapy showed a median overall survival of 7.92 months compared to 5.55 months with chemotherapy alone.
• A biomarker-enriched analysis revealed a 79% reduction in the risk of death in patients with higher pretreatment serum CEACAM1 levels.
• Purple Biotech plans to initiate a Phase IIb study to further evaluate CM24 in multiple tumor types based on NET and CEACAM1 expression.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath